Primary completion results for a Phase 3 study (NCT02224781) evaluating initial treatment sequences for BRAFV600 melanoma were posted on ClinicalTrials.gov on 2023-09-30. The study compared immunotherapy with ipilimumab and nivolumab to dabrafenib and trametinib, showing a 2-year overall survival of 68.3% for the immunotherapy arm versus 54.1% for the BRAF inhibitor arm (p=0.002).
Background
The study investigated treatment sequences for patients with Stage III-IV BRAFV600 melanoma. This trial explored the use of immunotherapy agents ipilimumab and nivolumab, which are monoclonal antibodies designed to help the body's immune system attack cancer. It also involved targeted therapy agents dabrafenib and trametinib, which are BRAF inhibitors used in melanoma with specific mutations.
Trial design
The Phase 3 study (NCT02224781) enrolled 267 participants with Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, or Unresectable Melanoma that contained a BRAFV600 mutation. The trial compared two treatment sequences: initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib (Arm A, Immunotherapy) versus initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab (Arm B, BRAF Inhibitor Therapy).
Key results
The trial reported the following 2-year Overall Survival (OS) outcomes:
- In Arm A (Immunotherapy), the 2-year OS was 0.683 (proportion of participants).
- In Arm B (BRAF Inhibitor Therapy), the 2-year OS was 0.541 (proportion of participants).
A Log Rank analysis indicated a p-value of 0.002 for the comparison between the two arms.
What this means
The results suggest that an initial treatment sequence involving ipilimumab and nivolumab followed by dabrafenib and trametinib may offer a statistically significant improvement in 2-year overall survival compared to the reverse sequence in patients with Stage III-IV BRAFV600 melanoma. The observed difference of 68.3% 2-year OS for the immunotherapy-first arm versus 54.1% for the BRAF inhibitor-first arm, with a p-value of 0.002, indicates a potential clinical benefit for prioritizing immunotherapy in this patient population. These findings could inform treatment sequencing strategies for unresectable BRAFV600 melanoma.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT02224781, titled "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma", were posted on 2023-09-30 on clinicaltrials.gov.